Immatics rises on data from early stage cell therapy trial
Source: SeekingAlpha
2025-06-02 15:40:12 ET
More on Immatics
- Immatics N.V.: Trading Below Cash, But Not Without Reason
- Seeking Alpha’s Quant Rating on Immatics
- Historical earnings data for Immatics
- Financial information for Immatics
Read the full article on Seeking Alpha
For further details see:
Immatics rises on data from early stage cell therapy trial
Militia Long/Short Equity ETF
NASDAQ: ORR
ORR Trading
-0.55% G/L:
$35.48 Last:
74,039 Volume:
$35.61 Open:
